COO

Business Context and Reporting Period

Company: The Cooper Companies, Inc. (COO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended January 31, 2026 (Fiscal Q1 2026)
Business Overview: The Company operates through two primary segments: CooperVision (contact lenses) and CooperSurgical (fertility and women's health care). The Company is a large accelerated filer incorporated in Delaware.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 6.2% year-over-year, driven by an 8% increase in CooperVision sales and a 3% increase in CooperSurgical sales. Favorable foreign exchange fluctuations contributed approximately $28.1 million to the growth.
• Profitability: Operating income rose 17% to $212.8 million, and Net Income increased 25% to $130.8 million. This was aided by a decrease in interest expense (down 14% due to lower average debt balances) and improved operating leverage in CooperVision.
• Segment Performance:
  • CooperVision: Operating income grew 14% to $210.2 million. Toric and multifocal sales grew 10%, while Sphere/other grew 5%.
  • CooperSurgical: Operating income grew 33% to $26.8 million, driven by sales growth and reduced SGA expenses, partially offset by higher R&D spend.
• Capital Allocation: The Company repurchased 1.1 million shares for $92.5 million during the quarter. There were no repurchases in the prior year period.
• Debt Structure: Short-term debt increased significantly to $620.7 million from $47.8 million, while long-term debt decreased to $1,879.0 million from $2,457.5 million. This reclassification reflects the maturity profile of the 2021 Term Loan.

Outlook, Risks, and Contingencies

• Outlook: Management remains optimistic about long-term prospects in contact lens and women's health markets, citing resilience in demand and growth in single-use modalities. However, they note risks from global macroeconomic conditions, inflation, and trade barriers.
• Subsequent Events (Debt Amendments): On February 3, 2026, the Company amended its 2021 Term Loan Agreement, extending the maturity of $950.0 million of term loans to February 3, 2031. The remaining $550.0 million retains its original maturity. The Company also amended its 2024 Revolving Credit Agreement to conform with these changes.
• Legal Contingency: On March 2, 2026, the U.K. First-tier Tribunal (FTT) issued a decision largely supporting HMRC in a dispute regarding payroll tax withholding related to the 2014 Sauflon Group acquisition. The Company intends to appeal. An adverse outcome could result in a loss ranging from £0 to £71.7 million plus interest. No liability has been recorded as the loss is not deemed probable.
• Risk Factors: Key risks include foreign currency fluctuations, interest rate volatility, supply chain disruptions, regulatory changes (e.g., EU MDR), and the impact of tariffs.

Investor Verification Checklist

• Debt Maturity Profile: Verify the impact of the February 2026 debt amendments on future liquidity and interest expense, specifically the extension of the $950 million term loan.
• UK Tax Dispute: Monitor the appeal process regarding the Sauflon Group payroll tax matter, as a loss up to £71.7 million remains a reasonably possible contingency.
• Foreign Exchange Sensitivity: Assess the sustainability of the $28.1 million favorable FX impact on sales, given the Company's significant international exposure.
• Share Repurchase Program: Confirm remaining authorization ($873.9 million) and future buyback activity under the $2.0 billion program.
• CooperSurgical R&D: Review the 20% increase in CooperSurgical R&D expenses to ensure alignment with expected product pipeline returns.